Results 101 to 110 of about 25,216 (236)

Hemophilia A: An Ideal Disease for Prenatal Therapy

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemophilia A (HA) is the most common inherited coagulation defect. Current state‐of‐the‐art treatment consists of frequent administration of prophylactic infusions of coagulation factor VIII (FVIII) protein or bispecific antibodies that replace the cofactor function of FVIIIa to maintain hemostasis. However, these treatments are far from ideal,
Christopher D. Porada, Anthony Atala, Graça Almeida‐Porada   +2 more
wiley   +1 more source

The tumor necrosis factor receptor superfamily in lung cancer immunotherapy: Therapeutic opportunities and challenges

Precision Medical Sciences, EarlyView.
TNFRSF members orchestrate a dynamic immunoregulatory network in lung cancer by coordinating co‐stimulatory and inhibitory signaling across immune cell populations, highlighting their potential as targets for precision immunotherapy. Abstract Immune checkpoint blockade has fundamentally reshaped the therapeutic landscape of lung cancer.
Bingjie Xue, Liling Dai, Li Dai, Xianglin Zuo   +3 more
wiley   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

EMB-01, a Tetravalent Bispecific Antibody, Inducing Co-Degradation of EGFR and c-Met for Enhanced Anti-Tumor Efficacy. [PDF]

Cancer Sci
As the breakthrough bispecific antibody targeting EGFR and c‐Met, EMB‐01 drives potent anti‐tumor efficacy by co‐degradation of both receptors. ABSTRACT The bispecific antibody EMB‐01 (bafisontamab), constructed using EpimAb's proprietary FIT‐Ig platform, is designed to simultaneously target epidermal growth factor receptor (EGFR) and receptor tyrosine
Gao J, Jiao X, Ren F, Wu X, Tan J, Bai Y, Dai Y, Shen L, Wu C, Shen L.   +9 more
europepmc   +2 more sources

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

G Protein–Coupled Receptors in Olfactory Signaling and Related Disorders: Mechanisms and Therapeutic Implications

Sensory Neuroscience, EarlyView.
This schematic highlights GPCRs as the central hub of olfactory signaling in health and disease. The central GPCR shows odorant activation and downstream pathways. Surrounding quadrants illustrate four GPCR‐mediated themes: odor perception and adaptation, mucosal immunity and regeneration, memory consolidation via neural circuits, and GPCR‐related ...
Zishuo Guo, Hongjie Du, Fanyu Yuan, Yuhan Dong, Fangyuan Zhu, Jian Liu, Chengzhilin Li, Xu Guo, Zhaoze Yang, Wenwen Qi, Ming Xia, Chengcheng Liu   +11 more
wiley   +1 more source

Dendritic Cell‐T Cell Crosstalk Mediated Cancer Immunotherapy

Exploration, EarlyView.
Ying Cai, Jiameng Chen, Yaping Li
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

bispecific antibody

Citation: 'bispecific antibody' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.12951 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual terms ...
openaire   +1 more source

Bispecific antibodies in follicular lymphoma

Haematologica
Bispecific antibodies, specifically anti-CD20 T-cell engaging constructs, are poised to alter the treatment paradigm of multiple B-cell malignancies, including follicular lymphoma. Two CD20xCD3 bispecific antibodies, mosunetuzumab and epcoritamab, are now approved in the United States for third-line or later treatment of follicular lymphoma.
Imran A. Nizamuddin, Nancy L. Bartlett
openaire   +3 more sources